Can Naturopaths Prescribe Ozempic? Rules, Weight Loss and Compounded Semaglutide

Published May 5, 2025
Updated
10 min read

Some can. Only a licensed naturopathic doctor (ND) in a state whose law lets NDs prescribe drugs like semaglutide may prescribe Ozempic. Unlicensed naturopaths, and NDs in states that don't license them, such as New York, can't. Ozempic is FDA-approved for type 2 diabetes, not weight loss, so prescribing it to someone without diabetes is off-label. The semaglutide brand approved for weight management is Wegovy.

Can Naturopaths Prescribe Ozempic? Rules, Weight Loss and Compounded Semaglutide

Which states let NDs prescribe Ozempic?

No state naturopathic board has published a rule or guidance specifically about GLP-1 drugs, as far as we found. So the answer comes from each state's general scope law. Our reading, as of October 2026:

StatusStatesWhy
Likely canArizona, New Mexico, Oregon, WashingtonNDs can prescribe most prescription drugs. Oregon requires the drug to be on its formulary. New Mexico requires a pharmacy exam. Washington follows board rules.
Only with conditions, or unclearCalifornia, Hawaii, Idaho, Maine, Montana, New Hampshire, North Dakota, Utah, Vermont, DCCalifornia NDs need a supervising physician for drugs other than hormones and epinephrine for anaphylaxis. Hawaii requires Board authorization for injectable forms. Idaho NDs prescribe from a formulary of non-controlled prescription drugs and need individual Board approval. Maine requires 12 months of physician collaboration first. North Dakota NDs need a prescribing endorsement, which requires a collaborative agreement with a supervising physician and a pharmacology exam, and then prescribe from a board formulary (NDCC 43-58-08 and 43-58-08.1). Montana's rules conflict. The rest are formulary-based or not verified.
CannotMaryland, Colorado, Connecticut, Kansas, Alaska, Massachusetts, Minnesota, Pennsylvania, Rhode Island, Wisconsin, New York and every state that doesn't license NDsNo prescribing authority, or a formulary that doesn't include drugs like semaglutide. Minnesota's law bars registered NDs from prescribing legend drugs (Minn. Stat. 147E.05). Massachusetts board guidance says NDs may not prescribe, dispense or administer prescription drugs (Massachusetts board, 2024). Rhode Island's law says doctors of naturopathy are not licensed to prescribe drugs (R.I. Gen. Laws 5-36.1-18). Wisconsin's law does not list legend-drug prescribing for its limited-scope NDs (Wis. Stat. 466.01(6)(a)).

For each state's full rules and sources, see our state-by-state rules for naturopathic prescribing. Rules change, so confirm with your state's naturopathic board.

Can a naturopath prescribe Ozempic without diabetes?

Only if the ND can prescribe semaglutide at all in their state. Even then, it would be off-label use. Ozempic's FDA label includes these uses (FDA label):

  • blood sugar control in adults with type 2 diabetes, alongside diet and exercise;
  • lowering the risk of major heart events in adults with type 2 diabetes and established heart disease;
  • lowering the risk of worsening kidney function, kidney failure and death from heart disease in adults with type 2 diabetes and chronic kidney disease.

Weight management is not on the Ozempic label. Using a drug for something its label doesn't cover is called off-label use. Two other drugs are FDA-approved for chronic weight management:

  • Wegovy (semaglutide 2.4 mg), approved in 2021 for adults with obesity, or overweight with at least one weight-related condition (FDA, 2021).
  • Zepbound (tirzepatide), approved in November 2023 (FDA, 2023).

Tirzepatide is also sold as Mounjaro, which, like Ozempic, is FDA-approved to help adults with type 2 diabetes improve blood sugar, alongside diet and exercise (Mounjaro prescribing information). Zepbound is the tirzepatide product approved for weight management.

If weight management is the goal, ask any prescriber, ND or otherwise, why they would choose Ozempic over a drug labeled for that use.

Ozempic vs Wegovy: what's the difference for an ND?

DrugActive ingredientMain FDA-approved use
OzempicSemaglutideType 2 diabetes; heart-risk reduction in adults with type 2 diabetes and heart disease; kidney-risk reduction in adults with type 2 diabetes and chronic kidney disease
WegovySemaglutide (2.4 mg)Chronic weight management (2021)
MounjaroTirzepatideType 2 diabetes (blood sugar control)
ZepboundTirzepatideChronic weight management (2023)

All four are prescription-only. For an ND, the legal question is the same for each: does the state's ND scope or formulary cover the drug? Formulary states list drugs individually, so check each one. Ask the prescriber how they confirmed both that your state lets NDs prescribe prescription drugs and that semaglutide falls inside that scope.

Compounded semaglutide from an ND or med spa

Compounded semaglutide is a pharmacy-made version of the drug rather than the brand product. Its legal status changed in 2025 (FDA, updated April 2026):

  • Semaglutide shortage ended: FDA declared it resolved on February 21, 2025.
  • Grace periods ended: FDA's leeway for state-licensed compounding pharmacies and physicians making copies ended after April 22, 2025. For larger outsourcing facilities, it ended on May 22, 2025.
  • Tirzepatide: FDA declared that shortage over in December 2024, and the compounding grace periods ended in March 2025.
  • As of April 2026: neither drug was on FDA's shortage list. FDA said it does not intend to act against a compounder that fills four or fewer prescriptions a month of a product that is essentially a copy of an approved drug.

In May 2026, FDA proposed leaving semaglutide, tirzepatide and liraglutide off its list of bulk ingredients that outsourcing facilities may use to compound drugs (Federal Register, May 1, 2026). The comment period was extended to July 30, 2026. We found no final decision as of October 10, 2026.

In February 2026, FDA said it intends to act against mass-marketed compounded GLP-1 drugs. It said these products are not FDA-approved and may not be marketed as generic versions of, or the same as, the approved drugs (FDA, 2026). Some state legislatures are also considering limits on GLP-1 compounding, according to the Oregon naturopathic board's February 2026 minutes.

If an ND or clinic offers compounded semaglutide, ask which pharmacy makes it, whether it's described as "generic Ozempic" (FDA says it can't be), and why they recommend it over an FDA-approved product.

What to ask before an ND prescribes a GLP-1

  1. License: What is your license number, and which state issued it? Look it up on the state board's website.
  2. State scope: Does our state let NDs prescribe semaglutide or tirzepatide? Do you need physician supervision or board approval for it? In Oregon, NDs can check a drug's formulary status with the board.
  3. The product: Is it Ozempic, Wegovy, Mounjaro, Zepbound or a compounded version? If compounded, which pharmacy makes it?
  4. Why this drug: If the goal is weight management, why this drug rather than one labeled for weight management?
  5. Labs and follow-up: What tests will you order before starting and while I'm on it? How often will we meet, and who do I contact about side effects? The Ozempic label doesn't set a lab schedule. It says kidney function should be monitored in people whose side effects could cause fluid loss, and people with diabetic retinopathy should be watched for eye problems.
  6. Coordination: Will you share records with my primary care doctor? If I have diabetes, how will you coordinate with whoever manages it?
  7. Cost: What does the drug cost each month, separate from visit fees? Do you sell it in-house, or do I fill it at a pharmacy?

Side effects and who shouldn't take it

These points come from the current Ozempic label on DailyMed, revised May 2026.

Boxed warning: risk of thyroid C-cell tumors. Semaglutide caused thyroid C-cell tumors in rodents. It is not known whether Ozempic causes them in people. The label says routine calcitonin blood tests or thyroid ultrasound are of uncertain value for catching medullary thyroid cancer early. While taking semaglutide, tell your clinician about a lump or swelling in the neck, hoarseness, trouble swallowing, or shortness of breath (MedlinePlus).

Who must not take it:

  • anyone with a personal or family history of medullary thyroid carcinoma (MTC);
  • anyone with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), or a family history of it;
  • anyone who has had a serious allergic reaction to semaglutide or any ingredient in the product.

Other serious warnings on the label:

  • acute pancreatitis;
  • complications of diabetic retinopathy (eye disease), especially in people with a history of it;
  • low blood sugar when used with insulin or with drugs that increase insulin release, such as sulfonylureas;
  • acute kidney injury from dehydration (fluid loss);
  • severe stomach and bowel side effects (Ozempic is not recommended for people with severe gastroparesis);
  • serious allergic reactions;
  • gallbladder disease, such as gallstones;
  • risk of inhaling stomach contents during general anesthesia or deep sedation;
  • pens must never be shared between people.

Most common side effects (in 5% or more of patients): nausea, vomiting, diarrhea, abdominal pain and constipation.

Go through your medical history, family history and current medicines with whoever prescribes it, and tell them before any surgery or procedure that needs anesthesia or sedation.

When to see an MD, DO or nurse practitioner instead

  • You live in New York or another state that doesn't license NDs.
  • Your state's ND scope doesn't clearly cover semaglutide, or the ND can't tell you how they confirmed it.
  • You have type 2 diabetes and already see a doctor for it, or you take other diabetes medicines.
  • You need insurance to cover a weight-management drug, and your plan says it only accepts prescriptions or prior authorizations from certain clinicians. Ask the plan first.
  • You're offered a compounded product and can't get clear answers about where it's made.

Common questions

Can a naturopath prescribe tirzepatide (Zepbound or Mounjaro)?

The same rules apply as for semaglutide. Tirzepatide is a prescription drug, so a licensed ND can prescribe it only where state scope covers it.

Can an unlicensed naturopath prescribe Ozempic?

No. Ozempic is prescription-only, and the prescriber must be authorized under state law. Traditional naturopaths, trained in non-accredited programs, aren't eligible for licensure (NCCIH).

Can a naturopath in New York prescribe Ozempic?

No. New York doesn't license naturopathic doctors, so an ND practicing there has no prescriptive authority (NY Senate S8714). A prescription would have to come from a clinician licensed to prescribe in New York.

Will insurance cover Ozempic if an ND prescribes it?

Ask your plan two separate questions: whether it covers the drug for your diagnosis, and whether it covers visits with an ND. See what naturopathic care costs and whether insurance covers it.

What to do next

Last reviewed: October 2026

Medical disclaimer. This article is for general education and is not medical advice. Talk to a licensed healthcare provider about your own situation. How we research and update articles.
Angela Vines
Written by

Angela Vines is an accomplished author and editor at NaturalHealingNow.com, where she is dedicated to empowering readers with the latest insights on natural and alternative health products. With a passion for holistic wellness, Angela believes in helping people live longer,...